One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Table 3

Characteristics and outcomes of PCV patients.

	Group	BCVA baseline (letters)	BCVA change at month 3	BCVA change at month 12	CRT baseline (μm)	CRT change at month 3	CRT change at month 12
1	PRN	69	9	15	357	−176	−164
2	PRN	69	8	8	367	−82	−112
3	PRN	72	16	15	415	−144	−201
4	PRN	67	12	22	653	−453	−441
5	LD	57	13	6	622	−342	−196
6	LD	43	34	40	413	−163	−130
7	LD	55	−3	3	457	−201	−203
8	LD	33	−9	−3	954	−126	−204

BCVA, best-corrected vision acuity; CRT, central retinal thickness; LD, loading doses; PCV, polypoidal choroidal vasculopathy; PRN, pro re nata.